IVAC

None

Plant alkaloid. FDA approved use on small-cell lung cancer, testicular cancer.

This drug should be coded

None

None

None

None

A prophylactic detoxifying agent used to inhibit hemorrhagic cystitis caused by ifosfamide. FDA approved for bladder protection when using cyclophosphamide (prevents bladder toxicity).

This drug should NOT be coded

None

Antineoplastic with alkylating activity. FDA approved.

This drug should be coded

None

FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.

This drug should be coded

None

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

This drug should be coded

None

None

None

On March 29, 2018: The FDA approved use of Leukine (sargramostim) to increase survival in adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS). Leukine can help patients with H-ARS by facilitating recovery of bone marrow cells that develop into white blood cells that help fight off infections.

This drug should NOT be coded